Dopamine agonist therapy for hyperprolactinemia

Brandon J. Bankowski, Howard A. Zacur

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations


Hyperprolactinemia significantly impairs the normal functioning of the reproductive system in women by its detrimental effects on gonadotropin secretion, ovarian follicular development, oocyte release, and corpus luteum function. Fortunately, hyperprolactinemia and the infertility that frequently accompanies it respond well to treatment with dopamine agonists, which inhibit pituitary prolactin release and thereby restore normal reproductive function. In addition, dopamine agonists usually facilitate the return of regular ovulatory menstrual cyclicity. Bromocriptine and cabergoline, the two dopamine agonists most commonly used for first-line treatment of hyperprolactinemia, have demonstrated efficacy even in the presence of pituitary adenomas. Cabergoline, with its improved tolerability, or other dopamine agonist alternatives may be used in patients who are intolerant of or resistant to bromocriptine. In amenorrheic, hyperprolactinemic women who desire to become pregnant, bromocriptine should be prescribed. However, women who are taking a long-acting dopamine agonist should discontinue the medication 1 month before trying to conceive.

Original languageEnglish (US)
Pages (from-to)349-362
Number of pages14
JournalClinical obstetrics and gynecology
Issue number2
StatePublished - Jun 1 2003

ASJC Scopus subject areas

  • Obstetrics and Gynecology


Dive into the research topics of 'Dopamine agonist therapy for hyperprolactinemia'. Together they form a unique fingerprint.

Cite this